

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Meeting of the Oncologic Drugs Advisory Committee (ODAC)
FDA White Oak Campus, Building 31, the Great Room (Rm. 1503)
White Oak Conference Center, Silver Spring, Maryland
June 25, 2014

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Caleb Briggs, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Aman U. Buzdar, MD

Vice President Clinical Research and Interim
Professor of Medicine
MD Anderson Cancer Center
Dept. of Breast Medical Oncology
Houston, Texas

Michael Menefee, MD

Assistant Professor
Division of Hematology and Oncology
Mayo Clinic
Jacksonville, Florida

Bernard F. Cole, PhD

Professor, Department of Mathematics and
Statistics
University of Vermont
Burlington, Vermont

Mikkael Sekeres, MD, MS

(Chairperson)
Associate Professor of Medicine
Staff, Cleveland Clinic Taussig Cancer Institute
Department of Hematologic Oncology and
Blood Disorders
Cleveland, Ohio

Tito Fojo, MD, PhD

Program Director, Medical Oncology
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Bethesda, Maryland

Antoinette J. Wozniak, MD, FACP

Professor, Department of Oncology
Wayne State University School of Medicine, and
Karmanos Cancer Institute
Detroit, Michigan

James Liebmann, MD

Assistant Professor of Medicine
Department of Medicine
University of Massachusetts
Worcester, Massachusetts

Jane Zones, PhD

(Consumer Representative)
Medical Sociologist (retired)
Breast Cancer Action
National Women's Health Network
San Francisco, California

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Meeting of the Oncologic Drugs Advisory Committee (ODAC)
June 25, 2014

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Howard Fingert, MD, FACP

(Industry Representative)

Senior Medical Director, Clinical Intelligence
Millennium, the Takeda Oncology Company
Cambridge, Massachusetts

TEMPORARY MEMBERS (Voting)

Peg A. Ford (Patient Representative)

Coronado, California

William P. McGuire III, MD

Medical Director
Gynecologic Cancer Outreach
Inova Fairfax Hospital
Falls Church, Virginia

Ralph Freedman, MD, PhD

Clinical Professor
Department of Gynecologic Oncology
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Edward L. Trimble, MD, MPH

Director
Center for Global Health
NCI, NIH
Rockville, Maryland

Brent Logan, PhD

Professor of Biostatistics
Division of Biostatistics
Medical College of Wisconsin
Milwaukee, Wisconsin

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Meeting of the Oncologic Drugs Advisory Committee (ODAC)
June 25, 2014

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director
Office of Hematology & Oncology Products
(OHOP),
Office of New Drugs (OND), CDER, FDA

Amna Ibrahim, MD

Acting Director
Division of Oncology Products 1 (DOP1)
OHOP, OND, CDER, FDA

Amy McKee, MD

Medical Team Leader
Breast/Gyn Team
DOP1, OHOP, OND, CDER, FDA

Geoffrey Kim, MD

Medical Officer
Breast/Gyn Team
Scientific Liaison – Gynecologic Malignancies
DOP1, OHOP, OND, CDER, FDA

Gwynn Ison, MD

Medical Officer
Breast/Gyn Team
DOP1, OHOP, OND, CDER, FDA